DRI Capital is a pioneer and global leader in healthcare royalty investing. Founded in 1992 as Drug Royalty Corporation, DRI Capital is the oldest and the largest healthcare royalty private equity fund manager in the world. In 2013, DRI closed its third managed fund, Drug Royalty III, with current equity commitments of US $1 billion from a global pool of institutional investors. This follows the successful raise in 2010 of U.S. $926 million of capital commitments for Drug Royalty II ($701M in equity for Drug Royalty II and $225M in equity for Drug Royalty II Co-Investment Fund), and the U.S. $800M raised in 2006 for Drug Royalty I ($240M in equity and $560M in debt). In 1993, Drug Royalty Corporation was listed on the Toronto Stock Exchange and remained publicly traded until 2002 when it was purchased, taken private and converted in to a global private equity fund manager business model. As of June 30, 2013, Drug Royalty I and Drug Royalty II have collectively acquired more than 40 separate international royalty streams from inventors, universities, research institutes, biotechnology and global pharmaceutical companies located around the world, payable on 29 different leading pharmaceutical products. Headquartered in Toronto, DRI Capital is a fully-integrated team of 30 investment professionals with deep life sciences industry expertise drawn from a variety of disciplines.